作者
J Mallet, Y Le Strat, F Schürhoff, N Mazer, C Portalier, M Andrianarisoa, Bruno Aouizerate, F Berna, L Brunel, D Capdevielle, I Chereau, T D'Amato, H Denizot, J Dubreucq, C Faget, F Gabayet, C Lançon, PM Llorca, D Misdrahi, R Rey, P Roux, A Schandrin, M Urbach, P Vidailhet, G Fond, C Dubertret, N Bazin, O Blanc, E Bulzacka, I Chereau-Boudet, G Chesnoy-Servanin, JM Danion, A Deloge, C Delorme, JM Dorey, C Fluttaz, S Fonteneau, E Giraud-Baro, D Lacelle, H Laouamri, M Leboyer, T Le Gloahec, E Metairie, I Offerlin-Meyer, C Passerieux, P Peri, S Pires, L Ramet, C Roman, A Tessier, AM Tronche, F Vaillant, A Vehier, E Vilà, H Yazbek, A Zinetti-Bertschy
发表日期
2017/10/3
期刊
Progress in Neuro-Psychopharmacology and Biological Psychiatry
卷号
79
页码范围
332-339
出版商
Elsevier
简介
Background
Tobacco use is common in patients with schizophrenia (SZ) but little is known on the role of tobacco in the physiopathology or on the course of the disease. Only few studies embrace an extensive examination of clinical and therapeutic characteristics in stabilized patients. The objective of the present study was to determine the prevalence of tobacco smoking in stabilized SZ outpatients and the clinical and treatment characteristics associated with daily tobacco use in a large community-dwelling sample of patients.
Methods
Three-hundred-and-sixty-one patients were included in the network of the FondaMental Expert Centers for Schizophrenia. Current tobacco status was self-declared.
Results
53.7% were smokers. Mean age at tobacco onset was 17.2 years old. In multivariate analyses, after adjustment for confounding factors, positive symptoms and mean daily antipsychotic dose were associated with a …
学术搜索中的文章
J Mallet, Y Le Strat, F Schürhoff, N Mazer, C Portalier… - Progress in Neuro-Psychopharmacology and …, 2017